Skip to main content
Log in

The Electronic Medication Event Monitor

Lessons for Pharmacotherapy

  • Current Opinion
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  1. Kass MA, Zimmerman T, Yablonski M, et al. Compliance to pilocarpine therapy [abstract no.2]. Invest Ophthalmol 1977; 108:2

    Google Scholar 

  2. Kass MA, Meltzer D, Gordon M. A miniature compliance monitor for ophthalmology. Arch Ophthalmol 1984; 102: 1550

    Article  PubMed  CAS  Google Scholar 

  3. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273–7

    Article  PubMed  CAS  Google Scholar 

  4. Averbuch M, Weintraub M, Pollack DJ. Compliance assessment in clinical trials: the MEMS device. J Clin Res Pharmacoepidemiol 1990; 4: 199–204

    Google Scholar 

  5. Kruse W, Weber E. Dynamics of drug regimen compliance: its assessment by microprocessor-based monitoring. Eur J Clin Pharmacol 1990; 38: 561–5

    Article  PubMed  CAS  Google Scholar 

  6. Tashkin DP, Rand C, Nides M, et al. A nebulizer chronolog to monitor compliance with inhaler use. Am J Med 1991; 91 Suppl. 4A: 33S–6S

    Article  PubMed  CAS  Google Scholar 

  7. Mawhinney H, Spector SL, Kinsman RA, et al. Compliance in clinical trials of two nonbronchodilator, antiasthma medications. Ann Allergy 1991; 66: 294–9

    PubMed  CAS  Google Scholar 

  8. Eisen SA, Woodward RS, Miller D, et al. The effect of medication compliance on the control of hypertension. J Gen Intern Med 1987; 2: 298–305

    Article  PubMed  CAS  Google Scholar 

  9. Cheung R, Dickins J, Nicholson PW, et al. Compliance with anti-tuberculous therapy: a field trial of a pill-box with a concealed recording device. Eur J Clin Pharmacol 1988; 35:401–7

    Article  PubMed  CAS  Google Scholar 

  10. Potter LS. Oral contraceptive compliance and its role in the effectiveness of the method. In: Cramer JA, Spilker B, editors. Compliance in medical practice and clinical trials. New York: Raven Press, 1991: 195–207

    Google Scholar 

  11. Urquhart J. Role of patient compliance in clinical pharmacokinetics: review of recent research. Clin Pharmacokinet 1994; 27:202–15

    Article  PubMed  CAS  Google Scholar 

  12. Urquhart J, Chevalley C. Impact of unrecognized dosing errors on the cost and effectiveness of pharmaceuticals. Drug Inf J 1988; 22: 363–78

    Google Scholar 

  13. Tritsmans L, Clincke G, Peelmans B. Does AAMI constitute a real disease entity? A placebo-controlled double-blind study with sabeluzole (R 58 735) in a patient population with real memory problems. Drug Dev Res 1990; 20: 473–82

    Article  Google Scholar 

  14. Matsui D, Hermann C, Braudo M, et al. Clinical use of the Medication Event Monitoring System: a new window into pediatric compliance. Clin Pharmacol Ther 1992; 52: 102–3

    Article  PubMed  CAS  Google Scholar 

  15. Matsuyama JR, Mason BJ, Jue SG. Pharmacists’ interventions using an electronic medication-event monitoring device’s adherence data versus pill counts. Ann Pharmacother 1993; 27: 851–5

    PubMed  CAS  Google Scholar 

  16. Steiner TJ, Catarci T, Hering R, et al. If migraine prophylaxis does not work, think about compliance. Cephalalgia 1994; 14: 463–4

    Article  PubMed  CAS  Google Scholar 

  17. Mason BJ, Matsuyama JR, Jue SG. Assessment of sulfonylurea adherence and metabolic control. Diabetes Educ 1995; 21: 52–7

    Article  PubMed  CAS  Google Scholar 

  18. Brun J. Patient compliance with once-daily and twice-daily oral formulations of 5-isosorbide mononitrate: a comparative study. J Int Med Res 1994; 22: 266–72

    PubMed  CAS  Google Scholar 

  19. Rudd P, Ahmed S, Zachary V, et al. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol Ther 1990; 48: 676–85

    Article  PubMed  CAS  Google Scholar 

  20. Kruse W, Eggert-Kruse W, Rampmaier J, et al. Compliance and adverse drug reactions: a prospective study with ethinylestradiol using continuous compliance monitoring. Clin Investig 1993; 71: 483–7

    Article  PubMed  CAS  Google Scholar 

  21. Mengden T, Binswanger B, Spühler T, et al. The use of selfmeasured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. J Hypertens 1993; 11: 1403–11

    Article  PubMed  CAS  Google Scholar 

  22. Kruse W, Rampmaier J, Ullrich G, et al. Patterns of drug compliance with medication to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther 1994; 32: 453–7

    Google Scholar 

  23. Cramer J, Vachon L, Desforges C, et al. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995; 36: 1111–7

    Article  PubMed  CAS  Google Scholar 

  24. de Klerk E, van der Linden SJ. Compliance monitoring of NSAID drug-therapy in ankylosing spondylitis, experiences with an electronic monitoring device. Br J Rheumatol 1996; 35: 60–5

    Article  PubMed  Google Scholar 

  25. Mallion JM, Dutrey-Dupagne C, Vaur L, et al. Comportement des patients ayant une hypertension arterielle legère a modrée vis-à-vis de leur traitement: apport du pilulier électronique. Ann Cardiol Angeiol 1995; 44: 597–605

    CAS  Google Scholar 

  26. Cramer JA. Microelectronic systems for monitoring and enhancing patient compliance with medication regimens. Drugs 1995; 49: 321–7

    Article  PubMed  CAS  Google Scholar 

  27. Girard P, Sheiner LB, Kastrissios H, Blaschke TF. A markov model for drug compliance, with application to HI V+ patients [abstract]. Clin Pharmacol Ther 1996; 59: 157

    Article  Google Scholar 

  28. de Klerk E, van der Linden SJ, van der Heijden D, et al. Facilitated analysis of data on drug regimen compliance. Stat Med. In press

  29. Rubin D. Comment: dose-response estimands. J Am Stat Assoc 1991; 86(413): 22–4

    Google Scholar 

  30. Urquhart J. Patient compliance as an explanatory variable in four selected cardiovascular studies. In: Cramer JA, Spilker B, editors. Compliance in medical practice and clinical trials. New York: Raven Press, 1991: 301–22

    Google Scholar 

  31. Efron B, Feldman D. Compliance as an explanatory variable in clinical trials. J Am Stat Assoc 1991; 86(413): 9–17

    Article  Google Scholar 

  32. Hasford J. Biometric issues in measuring and analyzing partial compliance in clinical trials. In: Cramer JA, Spilker B, editors. Compliance in medical practice and clinical trials. New York: Raven Press, 1991: 265–81

    Google Scholar 

  33. Sheiner LB, Rubin DB. Intention to treat analysis and the goals of clinical trials. Clin Pharmacol Ther 1995; 57: 6–15

    Article  PubMed  CAS  Google Scholar 

  34. Goetghebeur EJT, Pocock SJ. Statistical issues in allowing for noncompliance and withdrawal. Drug Inf J 1993; 27: 837–45

    Article  Google Scholar 

  35. Mäenpää H, Manninen V, Heinonen OP. Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. Eur Heart J 1987; 8 Suppl. I: 39–43

    PubMed  Google Scholar 

  36. Pullar T, Kumar S, Tindall H, et al. Time to stop counting the tablets? Clin Pharmacol Ther 1989; 46: 163–8

    Article  PubMed  CAS  Google Scholar 

  37. Pullar T, Feely M. Problems of compliance with drug treatment: new solutions? Pharm J 1990; 245: 213–5

    Google Scholar 

  38. Temple R. Dose-response and registration of new drugs. In: Lasagna L, Erill S, Naranjo CA, editors. Dose-response relationships in clinical pharmacology. Amsterdam: Elsevier, 1989: 145–67

    Google Scholar 

  39. Waterhouse DM, Calzone KA, Mele C, et al. Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993; 11: 1189–97

    PubMed  CAS  Google Scholar 

  40. Guerrero D, Rudd P, Bryant-Kosling C, et al. Antihypertensive medication-taking: investigation of a simple regimen. Am J Hypertens 1993; 6: 586–92

    PubMed  CAS  Google Scholar 

  41. Kruse W, Nikolaus T, Rampmaier J, et al. Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring. Eur J Clin Pharmacol 1993; 44: 211–5

    Article  Google Scholar 

  42. Benet LZ, Øie S, Schwartz J. Design and optimization of dosage regimens: pharmacokinetic data. Appendix II. In: Hardman JG, Limbird LE, Molinoff PB, et al. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1707–92

    Google Scholar 

  43. Benet LZ, Kroetz DL, Sheiner LB. Therapeutic drug monitoring. In Hardman JG, Limbird LE, Molinoff PB, et al. The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:26

    Google Scholar 

  44. Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990; 150: 1377–8

    Article  PubMed  CAS  Google Scholar 

  45. Rubio A, Cox C, Weintraub M. Prediction of diltiazem plasma concentration curves from limited measurements using compliance data. Clin Pharmacokinet 1992; 22: 238–46

    Article  PubMed  CAS  Google Scholar 

  46. Urquhart J. Correlates of variable patient compliance in drug trials: relevance in the new health care environment. In: Testa B, Meyer UA. Advances in drug research. London: Academic Press, 1995: 238–57

    Google Scholar 

  47. McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994; 50 Suppl. 1: S9–S195

    Article  Google Scholar 

  48. NORPLANT System. Physicians’ Desk Reference. 50th ed. Oradell (NJ): Medical Economics, 1996: 2759–64

    Google Scholar 

  49. Grimes DA. Clinical crossroads: a 17-year old mother seeking contraception. JAMA 1996; 276: 1163–70

    Article  PubMed  CAS  Google Scholar 

  50. British National Formulary, no. 32. Sep 1996: 338

  51. ORTHO-NOVUM Tablets. Physicians’ Desk Reference. 50th ed. Oradell (NJ): Medical Economics, 1996: 1872–80

    Google Scholar 

  52. Johnson BF, Whelton A. A study design for comparing the effects of missing daily doses of antihypertensive drugs. Am J Ther 1994; 1:260–7

    Article  PubMed  Google Scholar 

  53. Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol, andpindolol. Am Heart J 1982; 104:473–8

    Article  PubMed  CAS  Google Scholar 

  54. Houston MC, Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1988; 116:515–23

    Article  PubMed  CAS  Google Scholar 

  55. Gilligan DM, Chan WL, Stewart R, et al. Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy. Am J Cardiol 1991; 68: 766–72

    Article  PubMed  CAS  Google Scholar 

  56. Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta blockers. JAMA 1990; 263: 1653–7

    Article  PubMed  CAS  Google Scholar 

  57. Feinstein AR, Spagnuolo M. Experimental reactivation of subsiding rheumatic fever. J Clin Invest 1961; 40: 1891–9

    Article  PubMed  CAS  Google Scholar 

  58. Didlake RH, Dreyfus K, Kerman RH, et al. Patient noncompliance: a major cause of late graft failure in cyclosporinetreated renal transplants. Transplant Proc 1988; 20 Suppl. 3: 63–9

    PubMed  CAS  Google Scholar 

  59. Rovelli M, Palmeri D, Vossler E, et al. Noncompliance in organ transplant recipients. Transplant Proc 1989; 21(1): 833–4

    PubMed  CAS  Google Scholar 

  60. De Geest S. Subclinical noncompliance with immunosuppressive therapy in heart transplant patients: a cluster analytic study [dissertation]. Leuven: Catholic University Leuven, 1995

    Google Scholar 

  61. Cramer JA. Compliance with contraceptives and other treatments. Obstet Gynecol 1996; 88 Suppl.: 4S–12S

    Article  PubMed  CAS  Google Scholar 

  62. Petri H, Urquhart J. Patient compliance with beta-blocker medication in general practice. Pharmacoepidemiol Drug Saf 1994; 3: 251–6

    Article  Google Scholar 

  63. Guillebaud J. Any questions. BMJ 1993; 307: 617

    Google Scholar 

  64. QUESTRAN (cholestyramine). Physicians’ desk reference. 50th ed. Oradell (NJ): Medical Economics, 1995: 770–1

    Google Scholar 

  65. The Lipid Research Clinic. The Lipid Research Clinic’s coronary primary prevention trial results: (I) reduction in incidence of coronary heart disease; (II) the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 351–74

    Article  Google Scholar 

  66. Lasagna L, Hutt PB. Health care, research, and regulatory impact of noncompliance. In: Cramer JA, Spilker B, editors. Compliance in medical practice and clinical trials. New York: Raven Press, 1991:393–403

    Google Scholar 

  67. Vander Stichele RH, Thomson M, Verkoelen K, et al. Measuring patient compliance with electronic monitoring: lisinopril versus atenolol in essential hypertension. Post-marketing Surveillance 1992; 6: 77–90

    Google Scholar 

  68. Petzinna D. Electronic compliance measurement and fraud. A A Drug Information Association Workshop on Drug Compliance Issues in Clinical Trials & Patient Care. 1996 Sept 30-Oct 1; Paris, 12

  69. Kass MA, Meltzer D, Gordon M, et al. Compliance with topical pilocarpine treatment. Am J Ophthalmol 1986; 101: 515–23

    PubMed  CAS  Google Scholar 

  70. Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol 1986; 101:524–30

    PubMed  CAS  Google Scholar 

  71. Kass MA, Gordon M, Morley RE, et al. Compliance with topical timolol treatment. Am J Ophthalmol 1987; 103: 188–93

    PubMed  CAS  Google Scholar 

  72. Geletko, SM, Segarra M, Mayer KH, et al. Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women. Antimicrob Agents Chemother 1996; 40: 1338–41

    PubMed  CAS  Google Scholar 

  73. Bakker A, Paes AHP, Soe-Agnie C. Improving compliance of oral antidiabetics through pharmacist’s intervention [abstract]: proceedings of the 23rd European symposium on clinical trials and pharmacoharmaco-epidemiology. Pharm World Sci 1994; Suppl. 6: G28

  74. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996; 348: 383–6

    Article  PubMed  CAS  Google Scholar 

  75. Norell SE. Methods in assessing drug compliance. Acta Med Scand Suppl 1984; 683: 35–40

    PubMed  CAS  Google Scholar 

  76. Weis SE, Slocum PC, Biais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330: 1179–84

    Article  PubMed  CAS  Google Scholar 

  77. Wasson J, Gaudette C, Whaley F, et al. Telephone care as a substitute for routine clinical follow-up. JAMA 1992; 267: 1788–93

    Article  PubMed  CAS  Google Scholar 

  78. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190–5

    Article  PubMed  CAS  Google Scholar 

  79. Stanford ’Multifit’ CHF disease management program reduces ER visits by 52% in trial at Kaiser: medication compliance infrastructure is key, Stanford feels. Washington, DC, F-D-C Reports, 1 July 1996: 13-4

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to John Urquhart.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Urquhart, J. The Electronic Medication Event Monitor. Clin-Pharmacokinet 32, 345–356 (1997). https://doi.org/10.2165/00003088-199732050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199732050-00001

Keywords

Navigation